Pain outcomes in patients with advanced breast cancer and bone metastases (Q56550928)

7

Donald L. Patrick

0 references

Mark Clemons

8

Mark Clemons

0 references

Charles S Cleeland

1

Charles S. Cleeland

0 references

Norikazu Masuda

10

Norikazu Masuda

0 references

author name string

Jean-Jacques Body

2

0 references

Alison Stopeck

3

0 references

Roger von Moos

4

0 references

Susan D. Mathias

6

0 references

Katia Tonkin

9

0 references

Allan Lipton

11

0 references

Richard de Boer

12

0 references

Stefania Salvagni

13

0 references

Celia Tosello Oliveira

14

0 references

Yi Qian

15

0 references

Qi Jiang

16

0 references

Roger Dansey

17

0 references

Ada Braun

18

0 references

Karen Chung

19

0 references

language of work or name

English

0 references

publication date

5 September 2012

0 references

1 reference

16 August 2019

119

0 references

issue

4

0 references

page(s)

832-838

0 references

performing organization

University of Washington

University of Washington

1 reference

NIOSHTIC-2

on focus list of Wikimedia project

2 February 2024

Wikimedia–NIOSH collaboration

0 references

1 reference

25 September 2023

Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Pain and its treatment in outpatients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Measurement of health status. Ascertaining the minimal clinically important difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Fear of Pain in Patients With Advanced Cancer or in Patients With Chronic Noncancer Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Adaptation to metastatic cancer pain, regional/local cancer pain and non-cancer pain: role of psychological and behavioral factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

High prevalence of pain in patients with cancer in a large population-based study in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Biology of bone cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Metastatic bone pain: treatment options with an emphasis on bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

inferred from DOI database lookup

7 January 2021

based on heuristic

Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789

inferred from DOI database lookup

7 January 2021

based on heuristic

Unmet analgesic needs in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27789